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Abstract : Radiation damage to normal tissues is a serious concern in radiation therapy. Advances in radiothera-
peutic technology have improved the dose distribution of the target volumes and risk organs, but damage to risk 
organs that are located within the irradiation field still limits the allowable prescription dose. To overcome this 
dose-limiting toxicity, and to further improve the efficacy of radiotherapy, the development of drugs that protect 
normal tissues but not cancer tissues from the effects of radiation are expected to be developed based on molecu-
lar target-based drugs. p53 is a well-known transcription factor that is closely associated with radiation-induced 
cell death. In radiation-injured tissues, p53 induces apoptosis in hematopoietic lineages, whereas it plays a radi-
oprotective role in the gastrointestinal epithelium. These facts suggest that p53 inhibitor would be effective for 
radioprotection of the hematopoietic system, and that a drug that upregulates the radioprotective functions of 
p53 would enhance the radioresistance of gastrointestinal tissues. In this review, we summarize recent progress 
regarding the prevention of radiation injury by regulating p53 and provide new strategic insights into the devel-
opment of radioprotectors in radiotherapy. J. Med. Invest. 66 : 219-223, August, 2019
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INTRODUCTION
 
Recent progress high precision radiation therapy has been 
remarkable, and with improvements in dose distribution have 
resulted in much improved therapeutic effects. The prescription 
dose has improved by about 1.3 times compared the 4-field box 
technique (tolerance dose of 60 to 66 Gy) with the latest intensi-
ty-modulated radiation therapy IMRT (tolerance dose ~ 80 Gy) 
(1). However, because the complete segmentation of the target 
volumes and risk organs is often difficult in clinical settings, risk 
organs frequently suffer adverse events, especially risk organs 
that are located in the vicinity of the target lesion. The result 
is that the prescription dose is still limited by injury to normal 
tissue. It is especially true that, when the intestinal tract, a ra-
diosensitive tissue, is included in the irradiation field of the pel-
vic region, adverse events such as diarrhea, intestinal bleeding, 
ulceration, perforation, intestinal obstruction, and stenosis may 
occur in the form of early and late effects of intestinal disorders. 
In addition, because some tumors move with the movement of 
primary or surrounding organs such as by peristalsis, respira-
tion, and swallowing, a technological innovation for minimizing 
the damage of normal tissues is also necessary. Now that the 
physical technology has been optimized, it now becomes imper-
ative to further improve the tolerable dose by new technology. 
We believe that biological innovations will further improve the 
present tolerable dose. Therefore, our goal is to develop a normal 
tissue-selective radioprotective agent that permits a good value 
of dose reduction factor (DRF; the fold change in irradiation dose 
to produce a given level of biological effect). We initially set the 
target value of DRF to 1.3 and more, because a value of 1.3 is 
excellent protection activity comparable to DRFs achieved by the 
radioprotective agents developed so far (2, 3). 
For radiation protection, particularly important radiosen-
sitive organs are bone marrow and the intestinal epithelium. 
It is known that bone marrow death occurs with exposures of 
up to 10 Gy and gastrointestinal death predominates in a dose 
range from 10 to 50 Gy. These acute radiation syndromes are 
attributable to radiation sensitive stem cell death in each tissue. 
p53 is involved in the progression of radiation cell death, but its 
functions are completely different in each tissue. In bone mar-
row, it acts as a mediator of radiation-induced apoptosis, but it 
also acts as a resistance factor for non-apoptotic mitotic death 
in the intestinal epithelium (4). Thus, it would be necessary to 
rationally control p53 according to the radiation syndrome being 
considered.
CONVENTIONAL METHODS FOR PREVENTING 
RADIATION INJURIES USING ANTIOXIDANTS
Ionizing radiation generates reactive oxygen species (ROS) 
such as •OH and H2O2 through water-splitting reactions in the 
living body. ROS are highly reactive with respect to cell mem-
branes and DNA, leading to gene mutation and cell death. The 
use of antioxidants to scavenge ROS is a useful way for prevent-
ing radiation injury. In 1948, a few years after the atomic bombs 
were dropped in Japan, Patt et al. demonstrated that the amino 
acid cysteine, which contains a thiol group, showed radiopro-
tective effect in animal experiments (5). This finding attracted 
international attention especially from countries involved in the 
Cold War. Several thiol-containing radical scavengers were sub-
sequently developed as radioprotectors. Among them, amifostine 
(WR-2721, S-2 [3-aminopropylamino]-ethylphosphorothioic acid; 
Ethyol) is the most representative one (6).
Antioxidative agents should be administered prior to expo-
sure to radiation, since ROS production occurs at the moment 
of exposure. Although this type of agent is unsuitable for use in 
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unanticipated exposure situations such as the Fukushima and 
Chernobyl nuclear disasters, it has a great utility when used in 
a timely manner. The US Food and Drug Administration (FDA) 
currently approves amifostine as the only radioprotector aimed 
at protecting salivary glands in radiation therapy to head and 
neck cancers, but the dosage is strictly limited due to a variety 
of side effects (e.g. nausea, vomiting, and hypotension) (3, 6). In 
addition, most antioxidantive agents, including amifostine, also 
have a disadvantage, in that they increase radioresistance in 
cancer tissue due to their non-specific protective effects.
EFFICACY OF p53 REGULATION IN CANCER TRE-
ATMENT
In recent years, some protective agents have been devel-
oped that enhance radioresistance by controlling the molecular 
mechanism of cell death without relying on antioxidant activity. 
The p53 regulatory agent selectively protects normal tissue 
cells from radiation damage, which have, as a matter of course, 
normal p53 function. In contrast, the p53 regulatory agent does 
not protect many cancer cells from radiation injury, because 
nearly half of all types of cancer have lost their p53 function by 
oncogenic suppression or mutation. Therefore, the p53 regulato-
ry agent is expected not only to function as a radioprotector in 
nuclear disasters but also as a reducing agent for alleviating the 
side-effects associated with cancer treatment by overcoming the 
dose-limiting toxicities of radiation therapy and chemotherapy 
(Figure 1). Although the risk of promoting carcinogenesis as a 
disadvantage of p53 suppression is often pointed out, several 
studies have shown that this is not a concern by using genetical-
ly modified mice. These studies have reported that the genetic 
impairment of the apoptosis-inducing activity of p53 does not in-
crease carcinogenic risk, and its function as a tumor suppresser 
is independent from that of inducing apoptosis, cell cycle arrest, 
and senescence (7-9). Hence, transient pharmacological p53 
regulation is an ideal strategy for protecting normal tissues in 
cancer therapy.
SEARCHING FOR CHEMICAL COMPOUNDS THAT 
REGULATE RADIATION-INDUCED APOPTOSIS
In our initial attempts to identify chemical compounds that 
regulate radiation-induced apoptosis, we found that sodium 
orthovanadate (vanadate) acts on both the p53-mediated tran-
scription-dependent and -independent pathways, and protects 
mice from total-body 12 Gy-irradiation, which is a superlethal 
dose that kills bone marrow stem cells, and also produces severe, 
but not lethal effects itself, including damage to the intestines, 
a process that is generally referred to as gastrointestinal death 
(10). Vanadate was originally identified as an inhibitor of the 
induction of p41, which was detected in irradiated human T-cell 
leukemia MOLT-4 cells using a two-dimensional electrophoretic 
analysis (11). In subsequent experiments we found that p41 is a 
caspase-mediated cleavage product of a nuclear protein, called 
SETβ (p42) (12). However, vanadate had no direct inhibitory 
effect on caspase activity. Further analyses of the apoptotic 
pathway upstream of caspase activation revealed that vanadate 
inhibits p53. It is known that p53 acts as a transcription factor in 
an early response to radiation. In addition, it was also found that 
vanadate induced a conformational change in p53 to an inactive 
form without affecting the phosphorylation and accumulation 
of p53 after DNA damage, resulting in the loss of DNA binding 
activity and the transcriptional activity of p53 target genes. Fur-
thermore, the use of cell lines having different TP53 status and a 
p53 knockdown cell line revealed that the anti-apoptotic action 
of vanadate was required for p53, leading us to conclude that 
the target molecule of vanadate is p53 (13). Moreover, vanadate 
was superior to other known p53 inhibitors, such as pifithrin 
α (PFTα) (14) and PFTμ (15) in suppressing p53-dependent 
apoptosis, presumably because of its wide spectrum of anti-p53 
activities that inhibited not only the transcription-dependent 
pathway but the transcription-independent pathway as well, in 
which p53 directly acts on mitochondrial Bcl-2 family molecules. 
An excellent radioprotective activity was also demonstrated by in 
vivo radioprotection assays where vanadate rescued 60% of mice 
that had been treated with total-body 12 Gy-irradiation, a proce-
dure that killed all of the control mice that had been treated with 
vehicle or a representative p53 inhibitor, cyclic PFTα, within 12 
days. This result clearly indicated that vanadate was the first 
p53 inhibitor capable of rescuing gastrointestinal death induced 
by total-body irradiation (TBI) (10). In addition, a follow-up 
study revealed that vanadate functions, not only as a protective 
agent, but also as a mitigative agent when administered “after” 
the mice were exposed to radiation (16). These results suggest 
that the blockade of both p53 pathways is an excellent strategy 
for maximizing radioprotective effects by inhibiting the action 
of p53.
However, according to reports by other investigators, the inhi-
bition of apoptosis is effective for the protection of TBI-induced 
bone marrow death, but it is not effective for protection against 
gastrointestinal death. In addition, it was also reported that 
increasing p53 is effective for protection against gastrointestinal 
death (4). These conclusions were arrived at based on a series of 
an abdominal irradiation experiments called sub-total-body irra-
diation (SBI), designed to avoid bone marrow death by shielding 
the bone marrow of the mouse fore leg with lead. Indeed, an 
innate immune agonist CBLB502 (17), which activates the p53 
antagonist NF-κB, and also vanadate showed limited efficacy 
against gastrointestinal death by around 12 Gy. These results 
suggest that the efficacy of p53-suppressing radioprotectors may 
be limited to exposure below levels of about 12 Gy, in which the 
hematopoietic syndrome and gastrointestinal syndrome are 
combined. Therefore, in the case of a dose to the abdominal re-
gion that exceeds 13 Gy, enhancing the anti-cell death function 
Figure 1　Specific protection of normal tissues during cancer treat-
ment. A mutation in the TP53 gene that encodes p53 is found in nearly 
half of all human cancers. This is a major cause of differences in the 
biological response to various stimuli including radiation between 
normal and cancer tissues. The p53 regulator permits normal tissues 
having wild p53 to be specifically protected against DNA damage-in-
duced cytotoxicity, and is expected to function as a protective agent 
for the normal tissues during radiotherapy and chemotherapy.
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of p53 seems to be appropriate. It has also been shown that p21 
(Cdkn1 a)-deficient mice are susceptible to gastrointestinal death 
by abdominal irradiation. Moreover, super p53 mice, which have 
one more copy of Trp53, show resistance to intestinal death by ab-
dominal irradiation when compared with wild type mice. Taken 
together, the p53-p21 pathway is quite important for radioresis-
tance of the intestinal epithelium (4, 18). Clinically, severe bone 
marrow suppression is not assumed in radiation therapy, except 
for bone marrow transplantation, which is performed by TBI 
with a chemotherapeutic agent. Therefore, we decided to search 
for a new radioprotective agent, with the goal of protecting risk 
organs in the abdominal and pelvic region against radiotherapy. 
REGULATION OF p53 FUNCTION BY ZINC CHELA-
TION
We focused on the degenerative action of vanadate on p53 
that showed the highest radioprotective effect among the p53 
inhibitors tested (10). It is known that this denaturation action 
of p53 is caused by the dissociation of zinc ions (19) or substitut-
ing zinc with other metal ions (20) in zinc ion binding sites that 
are located between the DNA-binding domain of p53 and target 
DNA (Figure 2). Thus, a zinc (II)-chelating agent was considered 
as the first candidate for use as a new radioprotective agent. 
However, there are no reports showing that zinc (II) chelators 
inhibited p53-dependent apoptosis. In addition, there were 
concerns regarding the influence of the wide range of chelating 
toxicity. Therefore, we first attempted to search for zinc chelators 
(tridentate to hexadentate ligands) that inhibited p53-dependent 
apoptosis, in an attempt to show the p53 denaturation effect 
with low cytotoxicity. As a result, we found that Bispicen, a 
tetradentate ligand, had excellent p53 inhibitory effects and 
apoptosis inhibiting effects (21). Although Bispicen was able to 
inhibit p53-dependent apoptosis in cultured cells, it did not show 
protective effect against total-body irradiated mice, presumably 
due to its chelating toxicity.
8-HQ DERIVATIVES REGULATE p53 FUNCTIONS 
AND SUPPRESS RADIATION INJURIES
Therefore, we next searched for 8-hydroxyquinoline (8-HQ)-
based radioprotective agents. The characteristic feature of 8-HQ 
is that the ligands are bidentately coordinated to the zinc (II) ion 
(Figure 3A). These bidentate chelating agents generally have 
a low chelating activity, and would be expected to show a low 
toxicity to living cells and organisms. They were also expected 
to affect the DNA-binding activity of p53 by virtue of being 
accommodated into the niche between p53 and the target DNA 
without depriving p53 of a zinc ion. We investigated whether the 
synthesized 8-HQ derivative had an inhibitory effect against 
p53-dependent radiation-induced apoptosis, and found that 
several compounds showed anti-apoptotic effects (22). Among 
them, AS-2 (5,7-bis(N-methylaminosulfonyl)-8-hydroxyquinal-
dine) protected mice from an exposure of 8 Gy, which induces 
bone marrow death (Figure 3 B, C) (23). However, most of the 
8-HQ derivatives, including AS-2, that we have examined so 
far, except for 5-chloro-8-quinolinol (5CHQ), showed radiopro-
tective efficacies against bone marrow death, but had no effect 
on gastrointestinal death. The limited radioprotective efficacies 
appeared to be the limit of radioprotection by p53 inhibition, as 
predicted by results reported by Kirsch, et al. (4). However, we 
found that 5CHQ had a unique radioprotective activity during 
our evaluation of a series of 8-HQ derivatives. 5CHQ enhances 
the p53-mediated induction of antiapoptotic p21 and suppresses 
the induction of proapoptotic PUMA, which consequently leads 
to the prevention of p53-dependent cell death (2). The protective 
effect of 5CHQ on the mice bone marrow death after 7.5 Gy-TBI 
had a limited effect, with half of the mice being rescued. How-
ever, its pharmacological effect of enhancing p21 induction was 
considered to be effective for protecting against gastrointestinal 
damage. Therefore, we performed SBI to avoid bone marrow 
death, and examined the radioprotective effect on the acute 
gastrointestinal syndrome. As expected, 5CHQ showed a signif-
icant protective effect on the mice gastrointestinal death after 
SBI, and its DRF was 1.3, which has reached the original target 
value for radioprotection (Figure 4) (2). 
 
Figure 2　Structure of the p53/DNA complex created from the Pro-
tein Data Bank (PDB code : 1 TUP) (24) using a molecular viewer, 
Molmil (25). The p53 molecule contains a zinc ion (red sphere) locat-
ing at the binding site to target DNA. Three cysteines (yellow) resi-
dues and one histidine (blue) residue constitute a zinc-finger structure 
(represented by stick bond model) in the DNA binding domain of the 
p53 molecule (represented by ribbon model).
Figure 3　Radioprotective effects of AS-2, a derivative of 8-HQ, on 
radiation-induced hematopoietic injury. A, 8-HQ and zinc-ion com-
plex formation. B, Structural formula of AS-2. C, Thirty-day survival 
rates in mice after total-body X-irradiation. Female ICR mice (8 wks) 
received a single intraperitoneal injection of AS-2 (80 mg/kg) 30 min 
before 8 Gy of total-body X-irradiation. AS-2 rescued 100% of the mice 
from bone marrow death caused by the irradiation. (Modified form 
ref. 23)
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CONCLUSION
In this review, we summarize the efficacy of regulating p53 
for preventing radiation injuries. Among the p53 regulators ex-
amined by the authors, 5CHQ was found to have a quite unique 
property in that it increased p53 functions that are associated 
with radioresistance without inhibiting the activity of p53. This 
modulator may become a seed compound for developing new 
agents that assist cancer treatment in radiotherapy and chemo-
tharpy. Further studies will clearly be needed to clarify detailed 
pharmacological mechanism of 5CHQ and to assess potential 
clinical applications by using animal tumor models.
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